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1. Introduction
Pulmonary  embolism (PE)  is  the  most  lethal  pulmonary  condition  in  the  United  States
and internationally.  It  is  also the third most common cause of death in hospitalized pa‐
tients. Since the introduction of computed tomographic pulmonary angiography (CT-PA),
the estimated incidence of PE has risen from 62.1 to 112.3 cases per 100,000 [1]. Untreated,
the associated mortality of PE is as high as 30% with recurrent embolism being the most
common cause.  Globally,  systemic anticoagulation is  the mainstay of  treatment for  both
chronic and acute PE. In the case of acute massive PE (presenting with hypotension and
systolic arterial pressure less than 90 mm Hg) the prognosis is much graver and associat‐
ed with a mortality of 30-60%, second only to sudden cardiac death as a cause of sudden
death. This condition mandates a more aggressive and urgent algorithm for diagnosis and
treatment. Prompt and appropriate treatment, which may include surgical pulmonary em‐
bolectomy, can be life-saving.
2. Historical developments
The history of venous thrombosis and PE is intertwined with landmark developments in the
disciplines of anatomy, pathology, hematology, and surgery [2]. While pathologic observa‐
tions of postmortem pulmonary thrombi were detailed by Morgagni [3], Laennec [4], and
Cruveilhier [5] in the 18th and 19th centuries, it was not until the late 19th century that the
concept of thromboembolism was by recognized by Virchow. Virchow wrote “A plug may
extend into the vena cava as thick as the last phalanx of the thumb. These are the thrombi
that constitute the source of real danger; it is in them that ensues the crumbling away which
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leads to secondary occlusion in remote vessels” [6]. He was thus the first to ascribe a single
pathophysiologic mechanism to these anatomically separate phenomena (Figures 1 and 2).
Figure 1. Autopsy photo demonstrating a sudden fatal saddle embolism which occurred six days following pulmonary
lobectomy.
The surgical treatment of pulmonary embolism was first proposed by Friedrich Trendelen‐
burg, a German professor of surgery from Leipzig. Having studied the cases of nine patients
who died from acute pulmonary embolism, he developed a technique of pulmonary embo‐
lectomy through animal experimentation. His first two human patients died at 15 hours and
37 hours, from heart failure and hemorrhage of the internal mammary artery respectively
[7]. Trendelenburg’s student Martin Kirschner reported the first successful pulmonary em‐
bolectomy to the German Surgical Conference in Berlin in 1924 [8]. In Europe this became a
popular emergent bedside operation for patients in whom PE was strongly suspected. Surgi‐
cal residents were relegated to a bedside vigil and watched for sudden circulatory collapse
and respiratory compromise in high-risk patients. Fewer than 10 patients survived the oper‐
ation in 300 cases over a decade [2]. Though popular in Europe, the first successful pulmo‐
nary embolectomy was not reported in the United States until 1958 [9]. Operative mortality
was frequently due to myocardial ischemia resulting in ventricular fibrillation and death at
anesthetic induction [10]. The development of extracorporeal circulation by John Gibbon
was in fact stimulated by his reflections while keeping vigil over a patient who underwent
an unsuccessful attempt at pulmonary embolectomy: “…During the hours that night, John
watched the patient’s distended veins and recorded the faltering pulse, respirations and
blood pressure, the thought occurred to him and constantly recurred to him that her condi‐
tions could surely be improved if only there were some form of continuously withdrawing
some of the blue blood from the swollen veins into an apparatus where the blood could pick
up oxygen and discharge carbon dioxide, and then be pumped back into the patient’s arter‐
Principles and Practice of Cardiothoracic Surgery396
ies” [11]. This stimulated his work over the next twenty years to develop the heart-lung ma‐
chine, ultimately opening the doors to modern cardiac surgery and to the first successful
pulmonary embolectomy on cardiopulmonary bypass (CPB) by Edward Sharp in 1962 [10].
Figure 2. The saddle embolism isolated
Other surgical developments benefited from Virchow’s legacy by attacking the problem at its
more proximate source. The American surgeon Alton Ochsner, who had been present at
Kirschner’s 1924 address, proposed with Michael DeBakey to ligate the IVC in 1932 [12, 13].
John Homans, a general surgeon focused on venous disease, performed prophylactic lower ex‐
tremity vein ligation [14]. Caval interruption commonly resulted in chronic lower extremity
edema with the complications of varices, edema, and ulceration. As Spencer stated, “Because
of the morbidity often following ligation of the vena cava, it is probably used too seldom and
too late, being reserved as last resort...” [15]. Narrowing of the IVC via a right flank incision as
an adjunct to pulmonary embolectomy has also been described, with the authors abandoning
this technique due to impaired venous return [16]. Refinement of venous interruption came in
the form of the Miles clip [17], partial caval plication, and finally percutaneous intraluminal oc‐
clusive devices (Figure 3). Early occlusive devices were hampered by complications of migra‐
tion, embolization, vena cava wall rupture, and the need for femoral cutdown. Current filters
have evolved in ease of insertion, lower complication rates, and efficacy with long-term paten‐
cy rates of 98% and 3% recurrent embolism rates [18,19] (Figure 4).
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Figure 3. Vena Cava Filter.
Figure 4. Nitinol OptionTM Vena Cava Filter (Argon Medical Devices, Plano, TX). Features of contemporary filters in‐
clude retrievability, MRI compatibility, and percutaneous insertion.
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Concurrent with the developments in surgical techniques to treat PE were discoveries in an‐
ticoagulation. Heparin, discovered by McLean [20] and validated by Murray [21], has be‐
come the workhorse of initial therapy of PE. The discovery of oral dicumerol in the 1940s
has led to the use of anticoagulation as the mainstay of both prevention of and therapy for
venous thrombosis and PE. The efficacy of anticoagulants, thrombolytics, and vena caval fil‐
ters combined with the high mortality rate of pulmonary embolectomy, had led to a para‐
digm shift towards nonoperative management of acute massive PE.
3. Contemporary management: diagnosis and prognostication
Classification of PE was historically based on the angiographic burden, using the Miller In‐
dex [22]. Current classification by American Heart Association differentiates between mas‐
sive PE (sustained hypotension for at least 15 minutes or requiring inotropic support,
pulselessness, or persistent profound bradycardia) from submassive (acute PE without sys‐
temic hypotension but with either RV dysfunction or myocardial necrosis) (Table 1) [23].
Early identification and risk stratification is mandatory at the time of diagnosis in order to
coordinate multimodality treatment strategies. Prompt diagnosis and initiation of treatment
can reverse RV failure and reduce mortality. Current tools for prognostication include clini‐
cal parameters, radiographic findings, and laboratory markers.
Massive PE
Acute PE with sustained hypotension (Systolic blood pressure <90 mm Hg for at least 15
minutes or requiring inotropic support)
Not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or left
ventricular [LV] dysfunction
Pulselessness
Persistent profound bradycardia (heart rate<40 bpm with signs or symptoms of shock)
Submassive PE
Acute PE without systemic hypotension (systolic blood pressure <90 mm Hg) but with
either right ventricular (RV) dysfunction or myocardial necrosis
RV dysfunction means the presence of at least 1 of the following:
RV dilation (apical 4-chamber RV diameter divided by LV diameter > 0.9) or RV systolic
dysfunction on echocardiography
RV dilation (4-chamber RV diameter divided by LV diameter > 0.9) on computed
tomography
Elevation of beta-natriuretic peptide (BNP >90 pg/mL)
Elevation of N-terminal pro-BNP (> 500 pg/mL)
Electrocardiographic changes (new complete or incomplete right bundle-branch block,
anteroseptal ST elevation or depression, or anteroseptal T-wave inversion)
Myocardial necrosis is defined as either of the following:
Elevation of troponin I (>0.4 ng/mL) or
Elevation of troponin T (>0.1 ng/mL)
Table 1. American Heart Association Classification of Pulmonary Embolism [23].
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Clinical signs consistent with major PE include transient syncope, cyanosis, elevated jugular
venous pressure, tachypnea, unilateral restriction of chest wall movement, fever, and signs
of RV dysfunction (Table 2).
Clinical Signs of RV dysfunction
Left parasternal heave
Accentuated P2
Murmur of tricuspid regurgitation
Distended neck veins
Unilateral restriction of chest wall
Electrocardiogram Signs of
Right Heart Strain
RBBB
Right axis deviation
T-wave in V1-V4
Qr pattern in V1
P2 = pulmonic second heart sound
RBBB = right bundle branch block
RV = right ventricle
Table 2. Clinical and Electrocardiographic Signs of RV dysfunction [24]
Several scoring systems including the Pulmonary Embolism Severity Index [25] and Revised
Geneva Score [26] have been developed based primarily on clinical signs and history (Tables
3 & 4). They have been shown to have prognostic value [23] and do not require diagnostic
studies, making them a valuable tool for early prognostication.
Pulmonary Embolism
Severity Index
Score
Age 1 point per year
Male Sex 10
History of Cancer 30
History of Heart Failure 10
History of Chronic Lung Disease 10
Pulse > 110 beats/min 20
Systolic Blood Pressure < 100 mm Hg 30
Respiratory Rate > breaths/min 20
Temperature < 35 ˚C 20
Altered Mental Status 60
Arterial oxyhemoglobin saturation level <90% 20
Class Mortality Risk
Class I - < 65 points 0 - 1.6%
Class II - 65-85 points 1.7 - 3.5%
Class III - 85-105 points 3.2 - 7.1%
Class IV - 106-125 points 4.0 - 11.4%
Class V - >125 points 10.0 - 24.5%
Table 3. Pulmonary Embolism Severity Index [25]
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Revised Geneva Score Points
Age > 65 years 1
Previous DVT or PE 3
Surgery under general anesthesia or lower limb fracture within 1 month 2
Active malignant condition (solid or hematologic, currently active or considered cured < 1 year) 2
Unilateral lower limb pain 3
Hemoptysis 2
Heart rate 75-94 beats/min 3
Heart rate > 94 beats/min 5
Pain on lower limb deep venous palpation and unilateral edema 4
Clinical Probability
Low: 0 - 3 points
Intermediate: 4-10 points
High: >10 points
Table 4. Revised Geneva Score [26]
Biomarkers assessing the degree of right ventricular dysfunction associated with massive PE
that have been studied include troponin and beta-natriuretic peptide (BNP). Right ventricu‐
lar strain results in elevated troponin levels through acute shear stress causing microinjury
and microinfarction, as well as increased oxygen demand and diminished perfusion from an
acutely dilated and overloaded RV. Troponin levels have been found to correlate with the
presence of RV dysfunction [27,28], and cutoff values for troponin prognostication in PE are
identical to those in acute MI [29] while cutoff values for BNP are lower than those in con‐
gestive heart failure. Negative predictive value for both troponin and BNP are 97-100%;
however the positive predictive values are low, with a wide range of sensitivities and low
specificity for adverse events.
While most patients with suspected PE will have computed tomography angiography of the
chest, on occasion concerns for acute renal injury will prompt workup with ventilation-per‐
fusion scans. RV enlargement, defined as RV to LV dimension ratio > 0.9 on a reconstructed
CT 4-chamber view, has been found to correlate with echocardiographic findings of RV dys‐
function [30]. Subsequently, a study of 431 consecutive patients with acute PE found that RV
enlargement predicted 30-day mortality (15.6% vs 7.7%, hazard ratio 5.17) as well as the
composite end-point of death and in-hospital complications [31]. Dynamic CT assessment of
right ventricular response to reperfusion therapy or surgical embolectomy found that al‐
though RV enlargement persisted in 43%, significant reductions in mean RV dimension and
RV/LV ratio and significant increases in mean LV occurred with therapy, and did so equally
in patients treated with thrombolysis versus embolectomy. Patients presenting with cardio‐
genic shock had a greater degree of initial RV enlargement and a greater reduction post-
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therapy [32]. Echocardiography may demonstrate the McConnell sign of acute pulmonary
embolism, a characteristic pattern of akinesis of the mid free wall and normal motion of the
apex [33]. Other signs include right ventricular hypokinesis, right ventricle dilation, and
signs of pulmonary hypertension. In normotensive patients, RV dilation is present in 30-40%
and predicts in-hospital mortality as well higher non-resolution and recurrence of pulmona‐
ry thrombus burden [34].
4. Contemporary multimodality management
While chronic conditions such as heart failure and malignancy are responsible for most of
the late deaths in acute PE, early 30-day mortality results primarily from right ventricular
failure [31]. Contemporary diagnostic modalities such as computed tomography and echo‐
cardiography allow for improved risk stratification and patient selection for pulmonary em‐
bolectomy, while evolution of surgical techniques has prompted a renewed enthusiasm for
surgical pulmonary embolectomy as part of a multimodality approach to massive acute PE
(Figure 5). The indications for open surgical embolectomy have traditionally been for clearly
documented acute massive pulmonary embolism with persistent hypotension refractory to
maximal pharmacological support.
 
Anticoagulation 
Pharmacological 
Support 
Surgical Therapy 
Prevention of Re-
Embolization 
Systemic heparin 
Aggressive pharmacological cardiac support and 
ventilatory support with iNO 
Surgical pulmonary embolectomy 
Prevention of re-embolization with IVC filter 
Figure 5. Contemporary multimodality approach to treatment of acute massive PE
Multimodality treatment begins with immediate systemic heparinization at diagnosis, car‐
diogenic support with inotropic agents and vasopressors as indicated, and correction of hy‐
poxemia with supplemental oxygen or ventilatory support with pulmonary arterial
vasodilation using inhaled nitric oxide. The underlying critical pathology is acutely elevated
pulmonary vascular resistance (PVR) leading to pressure overload of the right ventricle and
acute RV distention. Through ventricular interdependence, LV filling is reduced, compro‐
mising cardiac output and oxygen delivery. (Figure 6). The initial goals of medical manage‐
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ment are optimization of RV preload and systolic function, reduction of pulmonary vascular
resistance, and maintenance of right coronary perfusion pressure by adequate aortic root
pressure [35]. Acute massive pulmonary embolism is initially a pressure overload problem
of the RV. Higher filling pressures may be required; however an altered Frank-Starling
curve in the setting of RV dysfunction may lead to volume overload as well. For patients
with low cardiac output and normal blood pressure, modest fluid challenges may be benefi‐
cial, and the use of dobutamine and dopamine is a class IIa recommendation. Class I recom‐
mendations include correction of systemic hypotension and use of vasopressors, although
the use of norepinephrine lacks clinical data, while the beneficial use of epinephrine in PE
with shock has been reported [36].
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Figure 6. Hemodynamic effects of acute massive PE
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RV function is coupled to pulmonary vascular resistance. Agents to reverse elevated PVR
may be intravenous, inhaled, or oral. All intravenous forms (prostacyclin, iloprost, sildena‐
fil, milrinone, and adenosine) carry the risk of systemic hypotension and should be institut‐
ed only after resuscitation and adequate perfusion of the RV. These agents may worsen the
ventilation/perfusion ratio, increasing the degree of pulmonary shunt. Inhalational agents
target the therapy to well-ventilated regions of the pulmonary bed, improving V/Q ratio and
decreasing shunt fraction. Inhaled nitric oxide (iNO) has been studied in ARDS, pulmonary
hypertension, and post mitral valve surgery, while evidence of its use in pulmonary embo‐
lism is limited to case reports and small case series. [37, 38, 39, 40]. While controlled studies
supporting its routine use as an adjunct are lacking, anecdotal evidence based on timing of
the institution of iNO seems to point to reductions in mean pulmonary artery pressures, in‐
creases in arterial oxygenation, and improvement in hemodynamics [38].
4.1. Surgical pulmonary embolectomy
The Trendelenburg operation was performed through a second transthoracic incision with
resection of the second rib, occlusion of the aorta and pulmonary artery with an encircling
rubber tube, and rapid removal of the embolism through a limited arteriotomy. Occlusion
was limited to “forty-five seconds to two minutes, beyond that, death occurs” [7]. Modern
surgical approach is by median sternotomy. After systemic heparinization, normothermic
CPB is instituted via aortic and bicaval cannulation. The vena cavae are encircled with um‐
bilical tapes. The operation is performed either with a beating heart and vacuum-assisted
venous drainage or with the heart arrested. Deep hypothermic circulatory arrest has also
been used in cases to optimize visualization for complete embolectomy [41]. The cavae are
snared to isolate right heart inflow. A longitudinal incision of the pulmonary trunk is made
two cm above the pulmonary valve. The extent of pulmonary arteriotomy is tailored to the
location of thrombus. The incision can be carried in a hockey-stick fashion onto the left main
pulmonary artery (Figure 7). For right-sided embolectomy, the right pulmonary artery is in‐
cised between the superior vena cava and the aorta. A variety of techniques of thrombus ex‐
traction have been described. Large clot can be retrieved with Randall stone forceps,
vigorous suction, and Fogarty embolectomy catheters passed into branch arteries. Opening
of the bilateral pleura and manual compression of the lungs to extrude peripheral clot has
been described but has the drawbacks of mechanical injury to the arterial walls and lung pa‐
renchyma, as well as possibly causing endobronchial bleeding [42].
Retrograde flushing via direct cannulation of the pulmonary veins from the left atrium has
been described to remove not only residual thrombotic material but air embolism as well.
As described by Zarrabi et al, if the right atrium is opened to look for suspected clot, a septal
incision through the fossa is then made, the left atrium entered, and the pulmonary veins
identified. A cannula is attached to the pump oxygenator, inserted into each pulmonary
vein sequentially, and flushed for 60-80 seconds with a mean pressure of 15-17 mm Hg. Clot
and debris thus flushed retrograde through the pulmonary veins is extracted through the
pulmonary arteriotomy [43]. If the right atrium is not entered, retrograde flushing of the left
atrium can be performed via a 20 Fr cannula. This is inserted through the right superior pul‐
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monary vein and attached to the arterial line through a Y connector [44]. Finally, adequate
visualization of the distal arterial tree can be extended with use of an arterioscope. Postoper‐
ative mortality in these patients is felt to be due to eventual right ventricular failure from
residual thrombus causing persistent pulmonary hypertension and interstitial pulmonary
edema [41]. However, data concerning which of the above techniques is best to remove
thrombus burden in the lungs, reduce RV strain, or improve outcomes is lacking. Intraoper‐
ative use of TEE during pulmonary embolectomy is recommended and can identify intra‐
thoracic extrapulmonary thromboemboli which may alter planned surgical maneuvers [45].
Reflecting back towards the original Trendelenburg procedure, inflow occlusion pulmonary
embolectomy is an option where CPB is not immediately available. This technique consists
of caval occlusion for 3-minute maximal periods, beyond which there is great risk of cardiac
and neurologic complications [46].
Figure 7. Technique of cardiopulmonary bypass with bicaval cannulation, arrows indicating direction of blood flow.
Randall stone forceps are inserted through the main pulmonary arteriotomy to extract a portion of embolus from the
left pulmonary artery. Inset: The three arteriotomy sites: main pulmonary artery, left and right pulmonary arteries
4.2. Contemporary surgical outcomes and expanded indications
A systematic review of pulmonary embolectomies in the period from 1961 to 2006 showed
the average mortality to be 30%. Several important factors in mortality included the time pe‐
riod, with higher mortality reported in studies before 1985 (32% vs 20%) and in patients
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with preoperative cardiac arrest (59% vs 29%) [47]. Prospectively studied patients that have
failed an initial course of thrombolytics have lower mortality with embolectomy than with a
second course of thrombolysis (7% vs. 38%) [48]. More recent studies have begun to examine
results in patients not meeting strict criteria of sustained hypotension or cardiogenic shock,
but rather using evidence of RV dysfunction as an expanded criteria for pulmonary embo‐
lectomy, with operative mortality in contemporary series being 6-8% [49-53]. Expediency of
operation has also found to have improved outcomes, particularly with surgical therapy oc‐
curring within 24 hours of diagnosis [54]. The improvement in operative mortality in the
modern era may be due to several factors: improved patient selection, early identification of
RV dysfunction with contemporary diagnostic modalities, extent of pulmonary thrombecto‐
my to prevent residual thrombus and thus pulmonary hypertension, the prophylactic use of
IVC filters, and early operation before the development of cardiogenic shock or the need for
cardiopulmonary resuscitation, both of which confer a significantly increased in-hospital
mortality (25% and 65%, respectively vs 8.1%) [55]. By instituting a criteria of RV dysfunc‐
tion as an indication for pulmonary embolectomy, the population to be considered expands
to include patients with submassive PE.
4.3. Thrombolytics, special populations, catheter-based therapy, and IVC filters
The benefit of thrombolytic therapy in the treatment of acute PE has been controversial. A
meta-analysis showed that overall, there was no significant reduction in PE or death when
comparing thrombolysis with heparin; neither was the risk of major bleeding significantly
increased. Subgroup analysis showed a significant reduction in PE and death in the trials
that included patients with major (i.e. hemodynamically unstable) PE and no benefit in
those trials that excluded those patients [56]. A review of current evidence concluded that,
“Despite the lack of a verifiable mortality benefit associated with thrombolytic therapy in
patients with massive PE resulting in hemodynamic instability, most clinicians accept this
clinical scenario as indication for thrombolytics and it is guideline based” [57]. In the most
recent guidelines (2012), The American College of Chest Physicians evidence for thrombo‐
lytic administration is graded 2C for unstable patients without high bleeding risk; recom‐
mendations are against thrombolytics in stable patients (Grade 1C) [58].
Because the effects are systemic, thrombolytics poses a risk of serious perioperative bleeding
and should be approached with caution in patients with acute massive PE that may be con‐
sidered for surgical embolectomy.
This decision is of particular interest in populations whose underlying disease places them
at increased risk of bleeding elsewhere. Trauma patients with immobility and/or traumatic
brain injury are prone to DVT and PE; sites of bleeding risk include concomitant solid organ
injury and intracranial hemorrhage. Reluctance to place prophylactic IVC filters has been
due to filter-related complications and inconsistent follow-up; this has been tempered by
more recent studies showing low complication rates and safe retrievability at greater inter‐
vals. Limited data consisting of matched-control trials have shown reduced PE and PE-relat‐
ed mortality rates with prophylactic filters [59]. Yet, prophylactic IVC filter placement in at-
risk patients remains a Level III recommendation by the Eastern Association for the Surgery
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Trauma guidelines [60]. Increased risk of both thromboembolic disease and intracranial
hemorrhage is seen also in patients with brain tumors. Successful pulmonary embolectomy
has been reported in a patient with advanced glioblastoma multiforme, suggesting that this
clinical scenario may represent an extended indication for surgery [61]. In patients with sig‐
nificant cardiac disease, pulmonary symptoms are often ascribed to cardiac etiology, but
rarely concomitant PE may be discovered [62], in which case surgical pulmonary embolecto‐
my may be combined with the operation to treat the primary cardiac disease.
Catheter-based techniques include aspiration thrombectomy, fragmentation, and rheolytic
thrombectomy. Rheolytic thrombectomy using the AngioJet and Rotarex devices has been
shown to be technically feasible with success rates of 92.2% to 100%, with significant im‐
provements in both angiographic indices and clinical indices (i.e, Miller Index, obstruction
index,  perfusion index,  mean pulmonary artery pressures,  partial  arterial  pressures)  [63,
64]. Data is limited to small series, and this therapy requires experienced laboratories. Its
role  as  primary  therapy  is  for  patients  with  contraindications  to  thrombolysis,  failed
thrombolysis, or impending death from shock prior to thrombolysis when no other inter‐
vention is available [58].
The placement of IVC filters is prudent even after treatment with pulmonary embolectomy
to prevent recurrent embolism from lower extremity sources. In several series, this has re‐
sulted in a zero recurrence rate [53, 65], while a 23% recurrence rate was noted in a series of
patients without IVC filter placement after embolectomy [48].
5. Conclusion
Acute massive pulmonary embolism is a disease best treated by multimodality therapy, be‐
ginning with systemic heparinization and IVC filter placement. A multitude of diagnostic
modalities, including transesophageal echocardiography and computed chest tomography,
are available in the contemporary setting to guide risk-stratification and to assess RV dys‐
function. Contemporary series of pulmonary embolectomy have demonstrated low opera‐
tive mortality with improved surgical techniques, and survival is increased when operative
therapy occurs before the development of hemodynamic collapse. Thus, the modified Tren‐
delenburg procedure with extended distal pulmonary embolectomy should be part of an ag‐
gressive approach to an otherwise lethal problem in the current age.
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